Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update-Reference-Cited by-同舟云学术

Use of Natalizumab in Patients with Multiple Sclerosis: 2015 Update

Published:2015-10-27 Issue:6 Volume:42 Page:372-380
ISSN:0317-1671
Container-title:Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
language:en
Short-container-title:Can. J. Neurol. Sci.

Author:

O’Connor Paul W.,Kremenchutzky Marcelo

Publisher

Cambridge University Press (CUP)

Subject

Clinical Neurology,Neurology,General Medicine

Reference44 articles.

1. O’Connor P , Goodman A , Kappos L , et al. Safety of natalizumab upon re-dosing: preliminary results from STRATA study. Poster presented at: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic.

2. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

3. Natalizumab Risk Stratification: Role of a Two- Step Anti-JCV Antibody Assay

4. Anti-JC Virus Antibody Prevalence in Canadian MS Patients

5. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab;Journal of Clinical Medicine;2023-12-19

2. Use of natalizumab in persons with multiple sclerosis: 2022 update;Multiple Sclerosis and Related Disorders;2022-09

3. Vaccine-associated measles in a patient treated with natalizumab: a case report;BMC Infectious Diseases;2020-10-14

4. Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study;Brain and Behavior;2019-06-06

5. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies;The Lancet Neurology;2017-11